Level of high sensitivity C-reactive protein in patients of acute myocardial infarction with or without diabetes mellitus
DOI:
https://doi.org/10.55958/jcvd.v18i3.104Keywords:
C-reactive protein levels, myocardial infarction, diabetes mellitusAbstract
Introduction: Myocardial infarction (MI) is diagnosed by history of typical angina chest pain of prolonged duration along with ST segment elevation and ECG and or raised cardiac biomarkers. Increased levels of CRP are associated with increased risk of HTN, DM and ischemic heart disease. Increased intake of trans fatty acids lead to increased levels of CRP, endothelial dysfunction and ischemic heart disease. Vessel wall is damaged after the inflammation and CRP is a marker of inflammation, so it can predict the cardiovascular disease.
Objective: The objective of this study is to determine the level of high sensitivity CRP in MI patients with or without diabetes mellitus.
Materials and methods: Total 60 patients were enrolled in the study. Patients having age from 40 to 70 years, diabetic patients and non-diabetic (male) and patients with acute myocardial infarcted patients were included. Patients having heart disease other than MI, patients less than 40 years were excluded. Level of high sensitivity CRP of patients of MI was analyzed by using chemiluminescence technique. High sensitivity CRP was analyzed quantitatively.
Results: In this study 60 individuals with AMI were divided into two groups based on presence(n=30) 50% and absence (n=30) 50% of diabetes mellitus. The mean age of the population was 58.32 ± 11.24 years. Levels of high sensitivity CRP were distributed in four groups, the first group includes hsCRP < 10 mg/l, group-2 includes hsCRP 11-50 mg/l, group-3 comprises levels of hsCRP from 51-100mg/l and group-4 includes hsCRP level from 101-150mg/l. Both groups of AMI patients without and with DM had significantly higher levels of hsCRP as 40% and 31% patients have CRP level lies in group 3 and group 4 respectively. Moreover, the diabetic patients had higher levels of hsCRP as 50% of diabetic patients having levels of hsCRP fall in category of group 3 whereas only 13.3% non-diabetic patients have hsCRP falls in category of group 3. And this difference is statistically significant with the p value (p=0.007).
Conclusion: The raised hsCRP is seen in AMI patients with history of diabetes, smoking and hypertension as compared to those AMI patients who had no previous history of all these risk factors.
References
Asmafreen P, Kalyani C, Madhusree B, Jagadeesh K, Venkatesh C, Vinod G, Kumar AV. A study on treatment patterns of revascularisation and its impact in single and double vessel disease at tertiary care hospital. World Journal of Pharmaceutical Research. 2020; 9(7): 2278-2302.
Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension?. Journal of hypertension. 2001 May 1;19(5):857-61.
Bellary S, Paul O'Hare J, Raymond NT, Mughal S, Hanif WM, Jones A, Kumar S, Barnett AH. Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study–effect of ethnicity on risk. Current medical research and opinion. 2010 Aug 1;26(8):1873-9.
Iqbal R, Jahan N, Hanif A. Epidemiology and management cost of myocardial infarction in North Punjab, Pakistan. Iranian Red Crescent medical journal. 2015 Jul;17(7)
Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, Yale SH. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. Wmj. 2016 Dec;115(6):317-21.
Dehghan A, Kardys I, de Maat MP, Uitterlinden AG, Sijbrands EJ, Bootsma AH, Stijnen T, Hofman A, Schram MT, Witteman JC. Genetic variation, C-reactive protein levels, and incidence of diabetes. diabetes. 2007 Mar 1;56(3):872-8.
Lopez-Garcia E, Schulze MB, Meigs JB, Manson JE, Rifai N, Stampfer MJ, Willett WC, Hu FB. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. The Journal of nutrition. 2005 Mar 1;135(3):562-6.
Lloyd-Jones DM, Liu K, Tian L, Greenland P. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Annals of internal medicine. 2006 Jul 4;145(1):35-42.
Goldman L (2011). Goldman's Cecil Medicine (24th ed.). Philadelphia: Elsevier Saunders. p. 54. ISBN 1437727883.
Polyakova EA, Mikhaylov EN. The prognostic role of high-sensitivity C-reactive protein in patients with acute myocardial infarction. J Geriatr Cardiol. 2020 Jul 28;17(7):379-383. doi: 10.11909/j.issn.1671-5411.2020.07.007.
Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, Davidson MH, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):621-35. doi: 10.1038/ncpcardio1322.
Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS; Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005 May;51(5):810-24. doi: 10.1373/clinchem.
de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: The Hoorn Study. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1086-93. doi: 10.1161/01.ATV.0000215951.36219.a4. Epub 2006 Mar 2. PMID: 16514084.
Mankowska A, Pollak J, Sypniewska G. Association of C-Reactive Protein and Other Markers of Inflammation with Risk of Complications in Diabetic Subjects. EJIFCC. 2006 Mar 20;17(1):8-11. PMID: 29795716; PMCID: PMC5954428.
Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020 Mar 6;21(5):1835. doi: 10.3390/ijms21051835.
Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol. 2004 May;24(5):969-74. doi: 10.1161/01.ATV.zhq0504.0173.
Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. Indian J Med Res. 2015 Sep;142(3):261-8. doi: 10.4103/0971-5916.166582. PMID: 26458341; PMCID: PMC4669860.
Jaiswal A, Tabassum R, Podder A, Ghosh S, Tandon N, Bharadwaj D. Elevated level of C-reactive protein is associated with risk of prediabetes in Indians. Atherosclerosis. 2012;222:495–501.
Rao VS, Kadarinarasimhiah NB, John S, Hebbagodi S, Shanker J, Kakkar VV. Usefulness of C-reactive protein as a marker for prediction of future coronary events in the asian Indian population: Indian atherosclerosis research study. Int J Vasc Med. 2010;2010:1–80.
